Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00226564
NCT00226564CompletedNot Applicable

The Effect of mu Opioid Receptor Polymorphism on the Response to Alfentanil During Lithotripsy

Hadassah Medical Organization1 site in 1 country100 target enrollmentStarted: August 1997Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
100
Locations
1
Primary Endpoint
Total alfentanil dose used during the procedure.
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The response to opioids varies greatly among individuals. Some of these variability is accounted for by genetic factors.

The present study was designed to evaluate the possibility that genetic polymorphism in the gene encoding for mu opioid receptor may explain variability in the response to alfentanil during lithotripsy.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
20 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age > 20

Exclusion Criteria

  • •Regular use of opioid drugs
  • •Known hypersensitivity to alfentanil

Outcomes

Primary Outcomes

Total alfentanil dose used during the procedure.

The extent of respiratory depression.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
MOR and COMT SNP Polymorphism and PainPain Relief
NCT00773760East Tallinn Central Hospital100
Unknown
Phase 2
Prediction of Inter-individual Differences in the Response to Morphine Versus Milnacipran in Patients With SciaticaNeuropathic Pain
NCT01914042Rambam Health Care Campus150
Completed
Not Applicable
Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African AmericansGenetic Underpinning of Substance AbusePolymorphism-geneticDrug Abuse/DependenceOpiod-Related Disorders
NCT02225184National Institute on Drug Abuse (NIDA)81
Completed
Not Applicable
Gene Polymorphisms and Morphine Analgesic ConsumptionGenePolymorphosis
NCT04621864Hamad Medical Corporation300
Completed
Phase 1
Opioid Induced Gait VariabilityOpioid Induced Motor Disturbances
NCT03121547Frederiksberg University Hospital24